Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AGN-151607-DP · 2 trials · 2 indications
TETRAS assesses participants' ability to function. Items are rated on a 5-category response scale from 0 (no tremor) to 4 (severe tremor).
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
PFC will be defined as the ability to achieve fascia to fascia midline approximation.
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
| Arm | Type | Description |
|---|---|---|
| AGN-151607-DP | EXPERIMENTAL | Participants will receive AGN-151607-DP. |
| Placebo for AGN-151607-DP | PLACEBO_COMPARATOR | Participants will receive Placebo for AGN-151607-DP. |
| AGN-151607-DP Dose A | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose A on Day 1. |
| AGN-151607-DP Dose B | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose B on Day 1. |
| AGN-151607-DP Dose C | EXPERIMENTAL | Participants will receive AGN-151607-DP Dose C on Day 1. |
| Name | Type | Description |
|---|---|---|
| AGN-151607-DP | DRUG | Intramuscular Injection |
| Placebo for AGN-151607-DP | DRUG | Intramuscular Injection |
Inclusion Criteria: * Minimum body weight of 50 kg (110 pounds) at Screening. * Diagnosis of essential tremor (ET) in accordance with the modified Tremor Research Investigation Group (TRIG) criteria, as follows: * Bilateral postural tremor with or without kinetic tremor, involving hands and fore...
AGN-151607-DP is an investigational small molecule being studied for ventral hernia and upper limb essential tremor. It is in Phase 2 clinical development for both indications. The drug is not approved and remains under investigation in clinical trials.
AGN-151607-DP is being developed by AbbVie Inc., traded on the New York Stock Exchange under the ticker ABBV. The company is conducting Phase 2 clinical trials for the drug in ventral hernia and upper limb essential tremor.
AGN-151607-DP is in Phase 2 clinical development. It is an investigational drug being studied for ventral hernia and upper limb essential tremor. The drug has not been approved by regulatory authorities and is still undergoing clinical trials.
AGN-151607-DP is being studied in two Phase 2 trials. NCT07226791 enrolls 200 adults undergoing open abdominal ventral hernia repair in the United States. NCT07673107 enrolls 94 adults with upper limb essential tremor in the United States. Both trials are recruiting participants.
AGN-151607-DP is a distinct investigational drug candidate developed by AbbVie. It is being studied for ventral hernia and upper limb essential tremor. No alternative names for this drug have been reported.